The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...
Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...
The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...
Explore more
Isomorphic Labs, the drug discovery start-up spun out of Google’s DeepMind artificial intelligence unit, has raised $600mn in its first external funding round, as investors bet on the potential for AI ...
Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...
Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...
AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...
Lilly and Novartis have collectively pledged almost $3 billion to their partnerships with Isomorphic signed last year, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results